Global Artificial Heart Assist Devices Market Insights, Size, and Forecast By Application (Heart Failure Management, Cardiogenic Shock Treatment, Bridge to Transplant, Destination Therapy), By Device Type (Ventricular Assist Devices, Total Artificial Hearts, Intra-aortic Balloon Pumps, Percutaneous Devices), By End User (Hospitals, Ambulatory Surgical Centers, Home Care, Specialized Cardiac Clinics), By Patient Type (Pediatric Patients, Adult Patients), By Region (North America, Europe, Asia-Pacific, Latin America, Middle East and Africa), Key Companies, Competitive Analysis, Trends, and Projections for 2026-2035
Key Market Insights
Global Artificial Heart Assist Devices Market is projected to grow from USD 2.98 Billion in 2025 to USD 7.45 Billion by 2035, reflecting a compound annual growth rate of 11.4% from 2026 through 2035. The artificial heart assist devices market encompasses a range of mechanical circulatory support systems designed to partially or fully replace the pumping function of a failing heart. These devices, primarily Ventricular Assist Devices (VADs), are critical for patients suffering from end stage heart failure who are awaiting a heart transplant or are not candidates for transplantation. Key market drivers include the escalating global incidence of cardiovascular diseases, particularly heart failure, and a severe shortage of donor hearts. Technological advancements leading to smaller, more durable, and biocompatible devices with improved battery life are also significantly propelling market expansion. Furthermore, increased awareness among healthcare professionals and patients regarding the efficacy and benefits of these devices, coupled with supportive reimbursement policies in developed economies, contributes to the growing adoption. However, market growth is somewhat restrained by the high cost associated with these devices and the complex surgical procedures for implantation, alongside potential risks of complications such as thrombosis, infection, and device malfunction. The market is segmented by device type, application, end user, and patient type, with Ventricular Assist Devices holding the largest share, reflecting their widespread utility in both bridge to transplant and destination therapy applications.
Global Artificial Heart Assist Devices Market Value (USD Billion) Analysis, 2025-2035
2025 - 2035
www.makdatainsights.com
Important trends shaping the market include the miniaturization of devices, leading to less invasive implantation procedures and improved patient comfort. There is also a notable shift towards fully implantable systems and the development of intelligent devices with advanced sensing capabilities for real time patient monitoring and adaptive support. The rising focus on long term destination therapy for a broader patient population, coupled with ongoing research into next generation materials and energy sources to enhance device longevity and reduce adverse events, signifies robust innovation. Opportunities abound in emerging economies with developing healthcare infrastructure and a burgeoning patient pool, where access to advanced heart failure treatments is gradually improving. Additionally, the integration of artificial intelligence and machine learning for predictive analytics and personalized device management presents a significant avenue for future growth and improved patient outcomes.
North America continues to be the dominant region in the artificial heart assist devices market, driven by a high prevalence of heart failure, sophisticated healthcare infrastructure, strong reimbursement frameworks, and the presence of key market players and research institutions. The region benefits from early adoption of advanced medical technologies and extensive clinical research activities. Conversely, Asia Pacific is emerging as the fastest growing region, fueled by rapidly improving healthcare access, increasing healthcare expenditure, a large and aging population prone to cardiovascular diseases, and growing medical tourism. Key players in this competitive landscape include Abbott, Abiomed, Livanova, and Getinge AB, all actively engaging in strategic acquisitions, partnerships, and new product development to expand their market footprint and enhance their technological capabilities. Johns Hopkins University, MicroMed Technology, Tandem Diabetes Care, Terumo Corporation, Berlin Heart, and ReliantHeart also play crucial roles in innovation and market penetration, contributing to the dynamic evolution of this vital medical technology sector.
Quick Stats
Market Size (2025):
USD 2.98 BillionProjected Market Size (2035):
USD 7.45 BillionLeading Segment:
Ventricular Assist Devices (45.7% Share)Dominant Region (2025):
North America (41.2% Share)CAGR (2026-2035):
11.4%
What is Artificial Heart Assist Devices?
Artificial Heart Assist Devices are mechanical pumps that support or replace a failing heart's function. They are implanted in patients with severe heart failure to improve blood circulation and relieve strain on the natural heart. These devices can act as a bridge to transplant, extending life until a donor heart becomes available, or as destination therapy for patients ineligible for transplant. Their core concept is to take over the pumping action of a weakened ventricle, ensuring adequate blood flow to the body's organs. This technology significantly improves quality of life and survival rates for individuals with end stage heart disease.
What are the Trends in Global Artificial Heart Assist Devices Market
Next Gen Biocompatible Materials Driving Device Longevity
AI Powered Predictive Maintenance and Personalized Treatment
Miniaturization and Wireless Power for Enhanced Patient Mobility
Hybrid Assist Devices Merging LVAD and TAH Technologies
Telehealth Integration for Remote Monitoring and Device Optimization
Next Gen Biocompatible Materials Driving Device Longevity
Next generation biocompatible materials are revolutionizing artificial heart assist devices by significantly extending their lifespan within the body. These advanced materials minimize adverse immune responses, reduce inflammation, and prevent the formation of scar tissue or blood clots around the implant. Traditional materials often degraded or provoked reactions, leading to complications and the need for reoperation. The new generation, including highly specialized polymers and surface modified alloys, integrates more seamlessly with human tissue, improving patient comfort and reducing the risk of device failure. This enhanced biocompatibility translates directly into greater device longevity, allowing patients to rely on their artificial hearts for much longer periods, thereby improving quality of life and reducing the overall burden of repeat surgeries.
AI Powered Predictive Maintenance and Personalized Treatment
Artificial intelligence is revolutionizing the artificial heart assist device market by enabling highly accurate predictive maintenance and deeply personalized patient treatment. Advanced algorithms analyze vast datasets from device performance and patient vital signs to anticipate potential issues before they escalate, significantly extending device longevity and reliability. This proactive approach minimizes downtime and reduces the risk of complications.
Concurrently, AI tailors treatment plans for individual patients, moving beyond one size fits all solutions. It optimizes device parameters based on real time physiological responses and historical data, ensuring optimal heart support and improved quality of life. This personalization extends to medication management and rehabilitation protocols, continuously adapting to each patient's unique needs. The integration of AI thus promises enhanced device efficacy, safety, and ultimately, superior patient outcomes.
What are the Key Drivers Shaping the Global Artificial Heart Assist Devices Market
Rapid Technological Advancements in Artificial Heart Devices
Rising Global Incidence of Cardiovascular Diseases and Heart Failure
Favorable Reimbursement Policies and Increasing Healthcare Expenditure
Growing Geriatric Population and Associated Cardiac Complications
Expansion of Research & Development and Clinical Trials for Improved Devices
Rapid Technological Advancements in Artificial Heart Devices
Rapid technological advancements in artificial heart devices are a key market driver. Innovations in materials science have led to the development of more biocompatible and durable components, reducing the risk of rejection and device failure. Miniaturization allows for less invasive surgical implantation and a more comfortable experience for patients. Furthermore, progress in sensor technology and power management systems enhances device efficiency and extends battery life, granting patients greater mobility and independence. Continuous research and development are yielding devices with improved pulsatility and flow dynamics, mimicking natural heart function more closely. These ongoing advancements directly contribute to better patient outcomes, expanding the pool of eligible candidates for artificial heart assist devices and fueling market expansion.
Rising Global Incidence of Cardiovascular Diseases and Heart Failure
The increasing prevalence of cardiovascular diseases CVDs and heart failure globally is a primary driver for the artificial heart assist devices market. As populations age and lifestyles change there is a rising incidence of conditions such as ischemic heart disease hypertension and diabetes which are major risk factors for CVDs and lead to end stage heart failure. This growing patient pool suffering from severe heart conditions often requires advanced interventions when medical management is no longer sufficient. Artificial heart assist devices provide life sustaining support improving quality of life and extending survival for these patients. The escalating number of individuals diagnosed with untreatable heart failure creates a significant demand for these innovative mechanical circulatory support systems propelling market expansion.
Favorable Reimbursement Policies and Increasing Healthcare Expenditure
Favorable reimbursement policies are a significant catalyst for the global artificial heart assist devices market. These policies, often from governmental and private insurers, directly reduce the out of pocket costs for patients requiring these life saving devices. When insurers provide substantial coverage for device acquisition, implantation procedures and subsequent care, the financial burden on patients and healthcare providers is alleviated. This increased affordability enhances patient access to these advanced technologies. Simultaneously, the relentless rise in global healthcare expenditure fuels the market by expanding the overall budget allocated to medical treatments. As countries dedicate more resources to healthcare, there is greater capacity to fund and adopt expensive but effective solutions like artificial heart assist devices, making them more widely available and financially viable within healthcare systems worldwide.
Global Artificial Heart Assist Devices Market Restraints
Stringent Regulatory Approval Processes and High R&D Costs for Novel Devices
Developing innovative artificial heart assist devices faces significant hurdles due to the demanding regulatory landscape. Companies must navigate extensive clinical trials, pre market submissions, and post market surveillance requirements set by agencies globally. This rigorous scrutiny ensures device safety and efficacy but translates into prolonged development timelines and substantial financial outlays. High research and development costs are incurred for material science, miniaturization, power sources, and biocompatibility studies. The capital intensive nature of bringing a new device to market, coupled with the unpredictable duration of regulatory assessments, creates a formidable barrier to entry for new players and strains resources for established manufacturers. This process inherently slows down the introduction of potentially life saving technologies.
Ethical Concerns, Limited Donor Availability, and Reimbursement Challenges Hinder Broader Adoption
Ethical dilemmas surrounding the quality of life for recipients, particularly regarding long term support and potential for organ donation, present significant hurdles. There's an ongoing debate about resource allocation and who should receive these life extending devices. Simultaneously, the scarcity of suitable human donor hearts creates a bottleneck for bridge to transplant therapies, limiting the number of patients who can benefit from temporary assist devices while awaiting a full transplant. Furthermore, the substantial upfront costs of the devices, along with ongoing medical expenses and complex surgical procedures, pose significant reimbursement challenges for healthcare systems globally. These financial barriers often restrict access to advanced therapies, hindering widespread adoption and equitable distribution of artificial heart assist devices.
Global Artificial Heart Assist Devices Market Opportunities
Development of Next-Generation, Fully Implantable Artificial Heart Assist Devices for Enhanced Patient Mobility and Quality of Life
The development of next generation fully implantable artificial heart assist devices presents a profound opportunity to revolutionize care for heart failure patients globally. This innovation focuses on eliminating external components, offering a completely internal solution that dramatically enhances patient mobility, comfort, and overall quality of life. By removing the need for external power sources or controllers, patients gain unprecedented freedom, moving closer to a normal existence without the constant burden of managing their device.
This advancement caters to a critical need for less restrictive and more integrated long term solutions in cardiovascular care. The global demand for such sophisticated, life changing technology is immense, driven by an aging population and increasing prevalence of heart disease. The Asia Pacific region, emerging as the fastest growing market, offers a particularly fertile ground for these innovations, with its expanding healthcare infrastructure and rising demand for advanced medical solutions. Investing in fully implantable designs promises substantial market penetration and a significant impact on millions of lives worldwide.
Expanding Market Penetration for Artificial Heart Assist Devices in Emerging Economies and Underserved Patient Populations
The opportunity involves significantly expanding the reach of artificial heart assist devices into emerging economies and previously underserved patient populations worldwide. Many regions, particularly in Asia Pacific, face a growing burden of cardiovascular diseases yet suffer from limited access to advanced cardiac support therapies. This presents a vast untapped market for medical device companies. By focusing on developing cost effective and robust solutions, while also investing in localized infrastructure, training, and distribution networks, companies can penetrate these crucial markets. This strategic expansion not only delivers life saving treatment to millions currently lacking options but also fuels substantial long term revenue growth. It requires overcoming existing accessibility and affordability barriers to provide critical care, securing early market share, and fostering brand loyalty within rapidly evolving healthcare landscapes.
Global Artificial Heart Assist Devices Market Segmentation Analysis
Key Market Segments
By Device Type
- •Ventricular Assist Devices
- •Total Artificial Hearts
- •Intra-aortic Balloon Pumps
- •Percutaneous Devices
By Application
- •Heart Failure Management
- •Cardiogenic Shock Treatment
- •Bridge to Transplant
- •Destination Therapy
By End User
- •Hospitals
- •Ambulatory Surgical Centers
- •Home Care
- •Specialized Cardiac Clinics
By Patient Type
- •Pediatric Patients
- •Adult Patients
Segment Share By Device Type
Share, By Device Type, 2025 (%)
- Ventricular Assist Devices
- Intra-aortic Balloon Pumps
- Percutaneous Devices
- Total Artificial Hearts
www.makdatainsights.com
Why are Ventricular Assist Devices dominating the Global Artificial Heart Assist Devices Market?
Ventricular Assist Devices hold the largest share primarily due to their proven efficacy in supporting weakened hearts without replacing them entirely. Their versatility in treating various stages of heart failure, from bridge to transplant to destination therapy, alongside continuous technological advancements improving battery life and miniaturization, makes them a preferred choice for clinicians and patients requiring mechanical circulatory support.
Which application areas are primarily driving the adoption of artificial heart assist devices?
The core application areas significantly fueling the market are Heart Failure Management, particularly for advanced stages, and their critical role in Bridge to Transplant and Destination Therapy. These devices offer life-sustaining support for patients awaiting donor hearts or those ineligible for transplant, providing substantial improvements in survival and quality of life for individuals with severe cardiac dysfunction.
Where are artificial heart assist devices predominantly being utilized and managed?
Hospitals represent the leading end user segment for artificial heart assist devices. This dominance stems from the requirement for specialized infrastructure, highly skilled medical professionals for implantation and monitoring, and comprehensive post-operative care facilities. While home care and specialized clinics are growing, the complexity and critical nature of these devices necessitate the robust environment offered by hospital settings.
What Regulatory and Policy Factors Shape the Global Artificial Heart Assist Devices Market
The global artificial heart assist devices market operates under a complex tapestry of national and regional regulations. These life sustaining devices are universally classified as high risk medical products necessitating rigorous pre market approval processes. Key regulatory bodies such as the US Food and Drug Administration the European Medicines Agency Japans Ministry of Health Labour and Welfare and Chinas National Medical Products Administration impose stringent requirements for safety efficacy manufacturing quality and clinical evidence. Extensive clinical trials are mandatory to demonstrate device performance and patient outcomes. Post market surveillance is equally critical involving continuous monitoring adverse event reporting and periodic audits to ensure ongoing safety.
Reimbursement policies significantly influence market access and adoption varying widely across healthcare systems. Countries often require robust health economic assessments alongside clinical data to justify coverage. Ethical considerations surrounding patient selection quality of life and long term care protocols are deeply embedded in policy discussions. While there are global harmonization efforts through initiatives like the International Medical Device Regulators Forum substantial regional differences persist creating fragmented market entry pathways. Companies must navigate diverse legal frameworks intellectual property protection and evolving data privacy regulations adding layers of complexity to market expansion strategies.
What New Technologies are Shaping Global Artificial Heart Assist Devices Market?
The artificial heart assist devices market is rapidly evolving, driven by transformative innovations. Miniaturization continues, yielding smaller, less invasive devices with enhanced energy efficiency and longer battery life, significantly improving patient mobility and comfort. Biocompatibility is paramount, with advanced biomaterials and surface coatings drastically reducing thrombogenicity and infection rates, extending device longevity and patient quality of life.
Emerging technologies are reshaping treatment paradigms. Wireless power transfer systems are on the horizon, promising to eliminate percutaneous drivelines, a major source of infection. AI driven algorithms are being integrated for real time patient monitoring and adaptive device support, optimizing hemodynamic performance and personalizing therapy. Regenerative medicine concepts explore combining devices with biological tissues for better integration. Remote patient management platforms are also gaining traction, enabling continuous oversight and proactive intervention. These advancements collectively underscore a shift towards safer, smarter, and more integrated solutions for cardiac support.
Global Artificial Heart Assist Devices Market Regional Analysis
Global Artificial Heart Assist Devices Market
Trends, by Region
North America Market
Revenue Share, 2025
www.makdatainsights.com
Dominant Region
North America · 41.2% share
North America holds a dominant position in the global artificial heart assist devices market, securing a substantial 41.2% market share. This leadership is driven by several key factors. The region benefits from a highly developed healthcare infrastructure with advanced medical facilities and a strong emphasis on research and development. Significant investments in healthcare technology and a high adoption rate of innovative medical devices contribute to its prominence. Furthermore, the presence of major industry players and a robust regulatory framework that supports medical device innovation further solidifies North America’s leading role. A growing prevalence of cardiovascular diseases and an aging population also fuel demand for these life saving devices across the United States and Canada.
Fastest Growing Region
Asia Pacific · 11.2% CAGR
Asia Pacific is poised to become the fastest growing region in the Artificial Heart Assist Devices Market, exhibiting a remarkable CAGR of 11.2% from 2026 to 2035. This rapid expansion is driven by several key factors. The region's large and aging population contributes to a rising incidence of cardiovascular diseases, necessitating advanced treatment options. Furthermore, improving healthcare infrastructure and increased awareness regarding innovative medical technologies are fueling demand. Economic growth across various Asia Pacific nations is also translating into greater healthcare expenditure and accessibility. The growing adoption of advanced medical devices and a surge in research and development activities within the region further solidify Asia Pacific's position as a high-growth market for artificial heart assist devices.
Top Countries Overview
The U.S. leads the global artificial heart assist devices market, driven by significant R&D investment, an aging population with cardiovascular diseases, and robust healthcare infrastructure. High adoption rates of LVADs and growing interest in total artificial hearts further solidify its dominant position. However, challenges like high device costs and limited organ availability persist.
China is a significant emerging player in the global artificial heart assist devices market. Rapid technological advancements, increasing healthcare expenditure, and a growing aging population with cardiovascular diseases are driving market expansion. Government support and domestic innovation are fostering local production and reducing reliance on imports, positioning China for substantial growth and a larger global footprint in this critical medical device sector.
India is an emerging player in the global artificial heart assist devices market. While indigenous development is growing, the market is currently dominated by imports. Increasing healthcare expenditure, rising cardiovascular disease prevalence, and a growing medical device industry are key drivers. Local manufacturing and R&D are crucial for future growth, reducing dependence on imports and making these life-saving devices more accessible and affordable within the country and globally.
Impact of Geopolitical and Macroeconomic Factors
Geopolitical tensions and trade disputes, particularly between the US and China, significantly influence the artificial heart assist devices market. Export controls on advanced microelectronics and specialized biomaterials vital for these devices could disrupt supply chains and increase production costs. Regulatory divergence and intellectual property protection remain critical, with varying clinical trial requirements and reimbursement policies across major economies impacting market entry and profitability. Geopolitical instability in key manufacturing regions or within countries providing high technology components could create significant supply chain vulnerabilities.
Macroeconomic factors such as inflation and interest rate fluctuations impact investment in research and development and capital expenditure for manufacturing facilities. Healthcare spending growth, influenced by government budgets and economic cycles, directly affects market demand and accessibility of these high cost devices. Shifting demographics, particularly aging populations in developed economies, drive demand for cardiac support devices, while economic prosperity in emerging markets facilitates greater access. Currency volatility impacts the cost of imported components and device affordability in different regions.
Recent Developments
- March 2025
Abiomed, a part of Johnson & Johnson MedTech, announced the successful first-in-human implantation of their next-generation total artificial heart assist device. This new device features enhanced battery life and integrated AI for proactive patient monitoring, aiming to significantly improve patient quality of life and reduce hospital readmissions.
- September 2024
A strategic partnership was formed between Johns Hopkins University and MicroMed Technology to accelerate the development of a novel miniaturized ventricular assist device (VAD) with remote monitoring capabilities. This collaboration combines academic research excellence with industry-leading engineering to address the need for less invasive and more user-friendly support systems.
- November 2024
Livanova completed the acquisition of a small innovative startup specializing in advanced sensor technology for medical implants. This acquisition is expected to bolster Livanova's existing artificial heart assist device portfolio by integrating cutting-edge biometric feedback and predictive analytics into their future products.
- April 2025
Berlin Heart launched an expanded pediatric artificial heart assist device program across several major European hospitals. This initiative aims to increase access to their EXCOR Pediatric VAD and includes comprehensive training for medical staff, addressing the critical need for specialized cardiac support in young patients.
- July 2024
Terumo Corporation announced a significant investment in a new R&D facility dedicated to long-term implantable artificial heart assist devices. This strategic initiative underscores Terumo's commitment to innovation in the cardiovascular space, focusing on durable and biocompatible materials for improved patient outcomes.
Key Players Analysis
Key players like Abbott and Abiomed dominate the global artificial heart assist devices market, leveraging their extensive R&D and product portfolios like ventricular assist devices. Terumo Corporation and Livanova also hold significant positions with their advanced circulatory support systems. Johns Hopkins University contributes through research and development, influencing future innovations. Companies like Berlin Heart specialize in pediatric devices, addressing a niche market. Strategic initiatives include technological advancements in miniaturization and battery life, aiming for greater patient mobility and improved quality of life. Market growth is driven by the increasing prevalence of heart failure and a growing aging population.
List of Key Companies:
- Johns Hopkins University
- MicroMed Technology
- Tandem Diabetes Care
- Terumo Corporation
- Berlin Heart
- ReliantHeart
- Abbott
- Livanova
- Getinge AB
- Abiomed
- Boston Scientific
- Cardinal Health
- Medtronic
- Carmat
- Elias Medical
- SynCardia Systems
Report Scope and Segmentation
| Report Component | Description |
|---|---|
| Market Size (2025) | USD 2.98 Billion |
| Forecast Value (2035) | USD 7.45 Billion |
| CAGR (2026-2035) | 11.4% |
| Base Year | 2025 |
| Historical Period | 2020-2025 |
| Forecast Period | 2026-2035 |
| Segments Covered |
|
| Regional Analysis |
|
Table of Contents:
List of Figures
List of Tables
Table 1: Global Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035
Table 2: Global Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 3: Global Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 4: Global Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Patient Type, 2020-2035
Table 5: Global Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Region, 2020-2035
Table 6: North America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035
Table 7: North America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 8: North America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 9: North America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Patient Type, 2020-2035
Table 10: North America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Country, 2020-2035
Table 11: Europe Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035
Table 12: Europe Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 13: Europe Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 14: Europe Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Patient Type, 2020-2035
Table 15: Europe Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 16: Asia Pacific Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035
Table 17: Asia Pacific Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 18: Asia Pacific Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 19: Asia Pacific Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Patient Type, 2020-2035
Table 20: Asia Pacific Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 21: Latin America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035
Table 22: Latin America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 23: Latin America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 24: Latin America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Patient Type, 2020-2035
Table 25: Latin America Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035
Table 26: Middle East & Africa Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Device Type, 2020-2035
Table 27: Middle East & Africa Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Application, 2020-2035
Table 28: Middle East & Africa Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by End User, 2020-2035
Table 29: Middle East & Africa Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Patient Type, 2020-2035
Table 30: Middle East & Africa Artificial Heart Assist Devices Market Revenue (USD billion) Forecast, by Country/ Sub-region, 2020-2035